John David Finley Sells 146,798 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) CEO John David Finley sold 146,798 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total transaction of $303,871.86. Following the transaction, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at $450,338.85. The trade was a 40.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palisade Bio Trading Down 3.9%

Shares of NASDAQ:PALI opened at $1.97 on Friday. The firm’s 50 day moving average is $1.92 and its two-hundred day moving average is $1.92. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86. The firm has a market capitalization of $341.95 million, a P/E ratio of -1.95 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wolfe Research began coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target for the company. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Oppenheimer set a $7.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Finally, Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PALI. XTX Topco Ltd grew its holdings in Palisade Bio by 53.8% during the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after acquiring an additional 7,584 shares during the period. Cetera Investment Advisers bought a new position in shares of Palisade Bio during the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at about $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio in the 4th quarter worth approximately $28,000. Finally, Atom Investors LP acquired a new position in shares of Palisade Bio in the 4th quarter worth approximately $33,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.